Whole-body PET Imaging of T-cell Response to Glioblastoma.

ABSTRACT:

Purpose

Immunotherapy is a promising approach for many oncological malignancies, including glioblastoma, however, there are currently no available tools or biomarkers to accurately assess whole-body immune responses in patients with glioblastoma treated with immunotherapy. Here, the utility of OX40, a costimulatory molecule mainly expressed on activated effector T cells known to play an important role in eliminating cancer cells, was evaluated as a PET imaging biomarker to quantify and track response to immunotherapy.

Experimental design

A subcutaneous vaccination approach of CpG oligodeoxynucleotide, OX40 mAb, and tumor lysate at a remote site in a murine orthotopic glioma model was developed to induce activation of T cells distantly while monitoring their distribution in s

SUBMITTER: Nobashi TW 

PROVIDER: S-EPMC8639766 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature